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Abstract
Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus. Toll-like receptor 7 (TLR7) is involved in host innate immunity
against pathogens, and its aberrant activation is linked to the development of systemic lupus erythematosus (SLE, also
called ‘‘lupus’’). Type I interferons (IFN) are apparently driving forces for lupus pathogenesis. Previously, we found that EBV
latent membrane protein 1 (LMP1) primes cells for IFN production. In this report, the relationship among EBV LMP1, TLRs,
and IFN production are examined. We find that TLR7 activation increases the expression of EBV LMP1, and IFN regulatory
factor 7 (IRF7) is involved in the stimulation process. TLR7 activation did not induce IFNs from EBV-infected cells, but
potentiates those cells for IFN production by TLR3 or TLR9 activation. In addition, we find that LMP1 and IFNs are co-
expressed in the same cells in some lupus patients. Therefore, the aberrant activation of TLR7 might induce LMP1
expression and LMP1-expression cells may be producing IFNs in lupus patients. These results suggest EBV might be an
exacerbating factor in some lupus patients via promoting IFN production.
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Introduction
Epstein-Barr virus (EBV) is a human gamma herpesvirus, and
associated with many different human diseases including mono-
nucleosis, systemic lupus erythematosus (SLE, also called lupus),
and several other diseases [1,2]. EBV transforms adult primary B
cells into continually growing lymphoblastoid cell lines and
concomitantly establishes type III latency in vitro [1]. EBV latent
membrane protein-1 (LMP1) is an integral membrane protein and
is required for the viral transformation process.
EBV establishes a lifelong persistent infection within peripheral
blood B cells with no or extremely low LMP1 expression [3,4].
LMP1 acts as a constitutively active, receptor-like molecule [5]
and activates a variety of cellular genes that enhance cell survival,
adhesive, invasive, and angiogenic potential. Remarkably, we have
found that LMP1 is an antiviral gene and primes cells for type I
interferon (IFN) production [6,7].
Lupus is a chronic, systemic, autoimmune disease that affects
about 0.1% of the US population. EBV has been linked to lupus
pathogenesis: EBV primary infection may be associated with the
onset of lupus in some patients [8,9,10]; certain EBV epitopes are
similar to auto-antigens presented in lupus patients [11,12]; and
higher EBV viral load, EBV antibodies, EBV seroconversion rates,
and EBV-infected B cells have been observed in lupus patients
[13,14]. The control of latent EBV infection is less effective in
lupus patients [15,16]. The expression of LMP1 RNA has been
shown to be associated with lupus [17] and LMP1 promotes
autoimmunity in certain rodent backgrounds [18].
Toll-like receptors (TLRs) are a family of evolutionarily
conserved receptors that recognize molecular patterns unique to
pathogens and activate host innate and adaptive immunity against
pathogens [19,20]. One of the major products from TLR
activation is the production of IFNs, key components to mount
a proper and robust immune response to a viral infection [21,22].
TLRs play critical roles in lupus pathogenesis. TLR7 is associated
with lupus progression [23,24,25,26]. In addition, the downstream
signaling components of TLR7, IFN regulatory factor 5 (IRF5)
and IRF7, are closely associated with lupus pathogenesis
[27,28,29,30,31,32]. Recognition of self-nucleic acids by TLR7
and TLR9 on plasmacytoid dendritic cells is considered to be a
key steps in IFN production in lupus and correlated with the
severity of disease [33,34]. Prolonged TLR3 may lead to
autoimmune reaction and aggravates lupus pathogenesis [35,36].
Type I IFNs are apparently a hallmark in lupus. IFN levels and
IFN-stimulated genes (ISG), collectively called IFN signatures in
some of the literature, are elevated in lupus patients [37,38,39].
The use of IFNs for the treatment of other diseases has caused
lupus-like syndromes [40,41]. Mice have failed to develop lupus
manifestations if the IFN receptor is deleted [42]. In addition, IFN
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promotes survival and differentiation of mature lymphocyhtes,
class switching at immunoglobulin heavy chain loci, and activation
of dendritic cells [43]. IFN also enhances the activation of B
lymphocytes by RNA-associated auto-antigens [44]. Therefore,
the IFN pathway has emerged as a focal point for understanding
mechanisms of autoimmunity in lupus.
We suspect LMP1 may contribute to lupus pathogenesis by
priming cells for IFN production, and have examined the relation
among LMP1, TLRs, and IFNs. We find TLR7 activation
increases LMP1 expression in EBV-infected cells, and potentiates
those cells for production of IFNs by TLR3 or TLR9 activation. In
addition, LMP1 and IFNs are co-expressed in the same cells in
some lupus patients. These results suggest EBV might be an
exacerbating factor in some lupus patients by responding to
aberrant TLR7 activation and promoting IFN production.
Results
TLR7 Stimulates the Expression of EBV LMP1
Because the LMP1 promoter region has a putative IRF
responsive element [45,46], TLRs have potential to activate IRFs,
and EBV-infected cells expressing TLRs, we reasoned that LMP1
might be regulated by TLR signals in EBV-infected cells. SavIII
and IB4 are EBV-transformed B cell lines with type III latency.
Cells were treated with various TLR agonists and 24 hours later,
Western blots were used to detect the expression of LMP1. As
shown in Figure 1, TLR7 agonist (imiquimod) induced expression
of LMP1 protein in two different EBV-infected cell lines.
However, TLR3 and -9 agonists did not induce the expression
of LMP1. TLR3, -7 and -9 are expressed in both cell lines (Figure
S1), and the TLR3 and 9 agonists were both effectiveness (data not
shown). Of note, IB4 is considered as prototype of EBV-
transformed cells in vitro and widely used in the research about
EBV transformation [47,48,49,50,51,52]. In addition, imiquimod
induced the expression of LMP1 RNA in both SavIII and IB4 cells
(Figure S1, data not shown).
It is known that LMP1 expression in EBV-infected cells exhibits
100-fold differences [53]. We therefore examined whether TLR7
activation increase the percentage of cells with high LMP1
expressions. Cells were treated with imiquimod and immune
stained with LMP1 antibody the next day. As shown in Figure 1B,
only a small proportion of cells were positive for LMP1 in EBV-
transformed IB4 cells. However under the exact same conditions,
the number of LMP1-positive cells was increased drastically upon
TLR7 activation and the differences are statistically significant
(Figure 1C). Similar results were also obtained in SavIII cells
(Figure S2). Therefore, TLR7 activation increases the population
of high LMP1 expressing cells in EBV-infected cells. Collectively,
all data suggest that TLR7 activation stimulates the expression of
EBV LMP1 in EBV-infected cells.
IRF7 is Involved in the TLR7-mediated LMP1 Induction
IRF7 is involved in the signaling of TLR7 [28,54]. Interestingly,
IRF7 was first discovered and highly expressed in EBV-
transformed cells and is a positive regulator for LMP1 [45,55].
It is possible that IRF7 is involved in TLR7-mediated induction of
LMP1.
To address the role of IRF7 in LMP1 induction, IRF-7-
dominant negative mutant (IRF7DN) was used [56]. A vector, or
IRF7DN and a CD4 expression plasmid were transfected into IB4
cells. Cells were split into two flasks, one of which was treated by
imiquimod. Transfected cells were enriched by the use of magnetic
beads for CD4 expressing cells [7,57,58]. As shown in Figure 2A,
TLR7 activation caused an increase in LMP1 protein expression
in vector-transfected IB4 cells as expected; however, IRF7-DN did
not enhance the expression (Figure 2A).
Similarly, we reduced the expression of IRF7 by small hairpin
RNA (shRNA) technology. Several shRNA for IRF7 plasmids
were transfected with CD4 expression plasmids, and the trans-
fected cells were enriched and examined. The induction of LMP1
was blocked when IRF7 expression was reduced (Figure 2B).
Therefore, IRF7 is involved in the TLR7-mediated induction of
LMP1.
EBV Lytic Replication Plays a Limited Role in the
Induction of LMP1
It has been reported that TLR7 activates Kaposi’s sarcoma-
associated herpesvirus, a close relative to EBV, lytic replication
from latently infected cells [59]. In addition, EBV LMP1 is
expressed during EBV lytic replication process [60]. Therefore, it
is possible that TLR7 activation leads to EBV lytic replication and
furthermore increases the expression of LMP1 indirectly.
To address the role of lytic replication in LMP1 induction, we
examined whether TLR7 activation leads to the induction of EBV
lytic replication. The expression of EBV EA-D (BMRF-1) was
used as a marker for lytic replication. The essential function of EA-
D in EBV lytic replication has been well established and EA-D as
an indicator of lytic replication has been widely used in the field
[61,62]. Because imiquimod did not obviously induce the
expression of EA-D in IB4 and Sav III cells (Figure S3), data
suggest that TLR7 activation might not induce EBV lytic
replication. Because, with our data, we cannot completely rule
out the involvement of low levels of lytic replication in LMP1
induction, we used BRLF1-knockout EBV (EBV-RKO) trans-
formed cells [63]. Viral lytic replication cannot be completed in
EBV-RKO transformed cells because BRLF1 is required for EBV
lytic replication [64]. EBV-RKO-transformed (LCL-RKO) and
the corresponding wild-type virus-transformed B lymphocytes
(LCL-wtEBV) were treated with TLR7 agonist. As shown in
Figure 3, imiquimod did induce the expression of LMP1 in both
wild type and RKO transformed cell lines. Furthermore, we
observed no evidence that lytic replication was induced in these
lines. Multiple bands for EA-D are a common phenomenon due to
phosphorylation (Figure 3B). Therefore, data in Figure 3 and
Figure S3 strongly suggested that viral lytic replication is not
involved in LMP1 induction by TLR7.
TLR7 Potentiates EBV-infected Cells for IFN Production
Because B lymphocytes express many TLR molecules, we tested
whether TLR agonist could activate IFN in EBV transformed
cells. IB4 cells were treated with various TLR agonists and ELISA
was used for the detection of multiple IFN-alpha subtypes in the
culture media. As shown in Figure 4, only TLR3 activation leads
to IFN production. TLR7 and 9 agonists could not (or could only
very marginally) induce IFNs (lanes 2, 3, and 5).
Because TLR7 activation stimulates the expression of LMP1,
we suspect that TLR7 is capable of priming cells for IFN
production via LMP1. IB4 cells were treated with TLR7 agonist
for 12 hours and the cells were further treated with TLR3 and -9
agonists for 24 hours. As shown in Figure 4, when cells were
treated with TLR3 and -9 agonists after TLR7 stimulations, both
produced more IFNs than those treated alone (lanes 4 and 6). The
combination of TLR3 and 9 agonists did not result in a synergistic
effect and the infection by Sendai virus resulted in much higher
levels of IFNs (data not shown). Sendai virus is a common IFN
inducer and can be used as a positive control. Therefore, the data
in Figure 4 suggest that TLR7 activation potentiates EBV-infected
cells for type I IFN production by TLR3 and -9 activations.
TLR7 Targets EBV LMP1
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EBV LMP1 and IFN are Expressed in the Same Cells in
Lupus Patients
Because TLR7 is associated with lupus, we suspect that EBV
may contribute to IFN production in lupus patients. We examined
20 lupus patients’ peripheral blood mononuclear cells (PBMC) by
immunocytochemistry analyses. Patients’ PBMCs were immedi-
ately fixed and processed for immunostaining for both IFN and
LMP1 expression. Because collection of different patients’ blood
took a long period of time, half of patients’ PBMCs were stored.
Once all 20 patients’ blood was collected, we thawed the stored
PBMCs and processed them simultaneously for all samples. The
specificity of the IFN-alpha Ab was confirmed Figure S4). DG75
(EBV-negative) and Sendai virus infected IB4 cells (EBV-positive)
were used as negative and positive controls, respectively. These
controls were used to set the proper settings for confocal
microscopy (Figures 5E, 5F). All samples were examined with
the same settings on the same machine.
With this assay, LMP1 was not detected in all six healthy
individuals (Table 1). Interestingly, we had detected that two out of
six healthy individuals (33%) had IFN-positive cells (Figure 1 and
Table 1). The results may be related to the fact that IFNs could be
induced by many factors, including some physiological stresses.
Also, these individuals were ‘‘apparently healthy’’ at the time of
blood collection. All lupus patients had detectable IFN-positive
cells, and the majority of them were also LMP1-positive (16 out of
20; 80%). The co-expression of IFN and LMP1 were detected in
the majority of patients (12/20; 60%) (Figure 5; Table 1).
Therefore, both IFN and LMP1 are highly expressed in lupus
patients; furthermore, IFN and LMP1 are co-expressed in the
same cells in some lupus patients.
Figure 1. TLR7 activation stimulates the expression of EBV LMP1. A. TLR7 agonist stimulates EBV LMP1. SavIII or IB4 cells were treated with
TLR7 agonist (imiquimod; 25 mg/ml), TLR3 agonist (poly (I:C); 10 mg/ml) or TLR9 agonist (ODN2395; 2.5 or 5 mM) for 24 hours. Cell lysates were used
for Western blot analysis with LMP1 and GAPDH antibodies. The identity of proteins is as shown. B. TLR7 activation increases detectable LMP1-postive
cells. IB4 cells were treated with imiquimod (25 mg/ml), for 24 hours, and the cells were fixed and stained with LMP1 primary and Alexa Fluor 647-
labeled secondary antibodies. DAPI was used to stain the nuclei. The images were captured under identical conditions. The colors were artificially
mounted to facilitate viewing. Blue, nuclei; red, LMP1. C. Quantification of detectable LMP1-positive cells. IB4 cells were treated and stained as in
Panel B. The percentages of LMP1-positive cells were counted in 10 randomly selected fields. For untreated controls, the average number of cells per
field with standard deviation is 201.5659.5; while in imiquimod treated cells, the average number of cells per field with standard deviation is
170.6670.8. The difference is statistically significant (p,0.01). The p value was calculated by paired Student’s t test with the use of Microsoft Excel.
doi:10.1371/journal.pone.0043317.g001
Figure 2. IRF7 is involved in the induction of LMP1. A. Dominant-negative mutant of IRF7 blocks the induction of LMP1. IB4 cells were
transfected with pcDNA3, or IRF7DN, along with CD4 expression plasmids. After 24 hours, the transfected cells were equally split into two flasks and
one was treated with imiquimod overnight (10 mg/ml). Transfected cells were enriched by the use of CD-4 positive selection kit. Cell lysates from were
used for Western blot analysis with LMP1 and tubulin antibodies. The identity of proteins is as shown. B. Reduction of IRF7 affects the induction of
LMP1. IB4 cells were transfected with shluc, or shIRF7 (mixture of IRF71, 72, and 73 at 1:1:1 ratio). The transfected cells were equally split into two
flasks for imiquimod treatment overnight and were enriched. Cell lysates were used for Western blot analysis with LMP1 and tubulin antibodies. The
reduction of IRF7 by shIRF7 is also shown. The images in the same box indicate that they are derived from the same membranes. The identity of
proteins is as shown.
doi:10.1371/journal.pone.0043317.g002
TLR7 Targets EBV LMP1
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Discussion
It is known that primary EBV infection leads to TLR7
inductions [65]. In this report, we provide evidence that TLRs
regulate EBV gene expression. First, TLR7 stimulates the
expression of LMP1 and increases the population of high-LMP1
expression cells (Figure 1), and the increase in LMP1 expression is
apparently at the RNA level (Figure S1). Second, TLR7 activates
IRF7 and EBV-latency cells express high levels of IRF7. We show
that IRF7 is involved in the TLR7-mediated induction of LMP1
(Figure 2). Third, because LMP1 was induced in a lytic-
replication-defective EBV-transformed B lymphocytes (LCL-
RKO) (Figure 3; Figure S3), the induction of LMP1 is apparently
not related to the EBV lytic replication process. We also tested
whether LMP1 could be increased further by TLR7 activation in
induced Akata cells. The results were not clear (data not shown).
We suspect that because lytic replication already induces the
expression of LMP1, the TLR7 activation may not be very
effective at that stage. In addition, Akata is a Burkitts’ lymphoma
line that already has some genomic mutations. In summary,
compelling evidence suggests that TLR7 regulates EBV LMP1
expression. Finally, it is known that LMP1 primes cells for IFN
production, and we find TLR7 actually primes EBV-infected cells
for IFN production induced by TLR3 and TLR9 (Figure 4).
Because LMP1 is required for the growth of the EBV-transformed
cells, ablation of LMP1 in EBV-transformed cells would have a
strong adverse impact on cellular growth; thus, the effects on IFN
production in the ablation of LMP1 would be hard to observe and
interpret. Therefore, our data simply suggest the association of
LMP1 with the synergy.
To examine whether the TLR7-LMP1 relation is operative in
vivo, we have examined PBMC from lupus patients because TLR7
activation is associated with lupus pathogenesis. We provide
evidence that EBV LMP1 protein is highly expressed in lupus
patients (Figure 5 and Table 1), confirming a previous report using
a different technique [17]. Because aberrant TLR7 activation is
associated with lupus pathogenesis, high LMP1 expression in lupus
might be related to the fact that TLR7 stimulates LMP1
expression in tissue cultured cells (Figure 1, 2, Figure S1).
Lupus patients have high IFNs or IFN signatures in PBMCs.
High levels of LMP1 may explain a high IFN signature in lupus:
LMP1 induces ISGs [7,66]. Our results therefore suggest a novel
mechanism for TLR activation to increase ISGs expression in
lupus patients. Furthermore, we find that LMP1 and IFNs are co-
expressed in the same cells in lupus’ PBMCs (Figure 5 and
Table 1). Although we do not know the identity of EBV-infected
cells in lupus at this time, the current data suggest that EBV-
infected cells are likely to be a source of IFNs in lupus patients.
The linkage between TLR7 and LMP1 expression is intriguing:
primary infection of B lymphocytes by EBV may induce the
expression of TLR7, IRF5, and IRF7 [55,65,67,68,69]. Further,
the type of viral latency cells with high TLR7, IRF-5, and IRF7
(type III) are probably present in lupus patients in vivo [12,70].
Because the type III latency cells are resistant to IFN-mediated
growth inhibition [71,72], those EBV-infected cells may be
preferentially propagated in lupus patients. TLR7 and -9
activations are associated with lupus, and the TLR7 and -9 dual
antagonists alleviate lupus pathogenesis [25,26,73,74]. In addition,
Figure 3. EBV lytic replication plays limited role in the
induction of LMP1. A. TLR7 activation induces LMP1 in EBV-
transformed cells defective for viral lytic replication. An EBV-BRLF-null
virus (RKO) transformed primary B cell line (LCL-RKO) and its parental
virus transformed cells (LCL-wtEBV) were treated with imiquimod
overnight. Cell lysates were used for Western blot analysis with LMP1
and tubulin antibodies. The identity of proteins is as shown. B. TLR7
activation failed to induce EBV lytic replication in EBV-transformed cells.
LCL-wtEBV and LCL-RKO cells were treated with imiquimod overnight.
The positive control was Akata cells treated with anti-human IgG. Cell
lysates were used for Western blot analysis with LMP1 and Tubulin
antibodies. The identity of proteins is as shown.
doi:10.1371/journal.pone.0043317.g003
Figure 4. TLR7 potentiates EBV-infected cells for IFN produc-
tions. IB4 cells were treated with TLR7 agonist (imiquimod; 5 mg/ml) for
12 hours, and the cells were then treated with TLR3 (poly (I:C); 10 mg/
ml) or TLR9 agonist (ODN2395; 5 mM) for 24 hours. Medium was
collected for ELISA. Average of duplicates is as shown. One
representative from three independent experiments is as shown.
doi:10.1371/journal.pone.0043317.g004
TLR7 Targets EBV LMP1
PLOS ONE | www.plosone.org 4 August 2012 | Volume 7 | Issue 8 | e43317
high LMP1 expression is associated with lupus severity [17]. In our
experimental system, TLR7 itself hardly induces IFNs by B
lymphocytes, but potentiates IFN production by TLR3 or TLR9
agonists in EBV-infected cells (Figure 4). Therefore, our data
correlate well with the known roles of TLR7and -9 in lupus
pathogenesis, and suggest an exacerbating cycle in lupus patients:
EBV infection induces TLR7 expression; TLR7 activation
promotes LMP1 expression; LMP1 might potentiate the cells for
IFN production by TLR3 and TLR9 agonists; and high amounts
of IFNs would promote more auto-antibody productions, cell/
tissue damages, and eventually more self-nucleotide complexes to
activate TLRs [75,76,77,78], which may again promote LMP1
expression (Figure 6). Because some case reports suggest that
primary EBV infection is associated with the onset of lupus
[8,9,10], it is tempting to speculate that EBV may even play an
etiological role in some lupus-susceptible individuals as both an
initiator and an exacerbating factor in IFN productions and
furthermore the development of the diseases.
LMP1 is a primary oncoprotein for viral transformation [2].
Our results suggest that lupus patients may have high incidence of
EBV-associated lymphomas. Actually, lupus patients exhibit three-
to four-fold increase in the risk of developing B cell malignancies
[79,80], and EBV may be associated with some lymphomas
[81,82]. In addition, EBV is a factor and associated with
Hodgkin’s and non-Hodgkin’ lymphomas in AIDS patients.
Because HIV activates TLR7 pathway [83], the linkage between
TLR7 and EBV might play a role in the development of AIDS-
associated lymphomas.
In summary, we have provided evidence that TLR7 activation
for the enhanced LMP1 expression and this mechanism may be
present in lupus in vivo. These data may support EBV as an
exacerbating agent in the development of lupus through modu-
lation of IFNs.
Materials and Methods
Cell Culture, Plasmids, Sendai Virus, and Western Blot
Analysis
DG75 and Akata are EBV-negative and EBV-positive Burkitts’
lymphoma cell lines, respectively [84]. SavIII, IB4, LCL-wtEBV,
and LCL-RKO are all EBV-transformed cell lines in vitro
[48,63,85]. LCL-wtEBV, and LCL-RKO were obtained as gifts
from Dr. Shannon Kenney [48,63,85]. These cells were main-
tained in RPMI-1640 plus 10% fetal bovine serum (FBS; Gibco
BRL) and 1% Penicillin-streptomycin (PS) at 37uC in 5% CO2
incubation. Sendai virus stock was purchased from Spafas, Inc.
For Sendai infection, 5–10 HA units/ml Sendai virus were added
to the target cells for 12 hours. Cells then were fixed for further
analysis. 293T is a human fibroblast line (from ATCC) and were
grown in Dulbecco’s modified Eagle medium (DMEM, Gibco
Figure 5. EBV LMP1 is localized in the IFN-producing cells in lupus patients. PBMCs from healthy or lupus patients were stained with IFN
and LMP1 antibodies. Alexa Fluor 488- and Alexa Fluor 647-labeled secondary antibodies were used to distinguish the signals from IFN and LMP1,
respectively. DAPI was used to stain the nuclei. The colors were artificially mounted to facilitate viewing: blue, nuclei; green, IFN; red, LMP1. Panel A: A
representative result for apparent healthy individual is shown. Panel B: Result for lupus patients (Patient #7 in Table 1) is shown. Circle: dual-positive
cells. Arrow: LMP1 single positive cell. Square: IFN- single positive cell. Panel C: Healthy individual #5. Arrow indicates an IFN-positive cell. Some red
blood cells are presents (no nuclei); Panel D: Result for lupus patients #11: arrows indicate the IFN-positive cells; Panel E: DG75 cells (negative
control); Panel F: IB4 cells infected with Sendai virus (positive control). Panels: C–F: a, IFN only; b, LMP1 only; c, IFN plus LMP1; and d, IFN, LMP1, and
nuclei.
doi:10.1371/journal.pone.0043317.g005
TLR7 Targets EBV LMP1
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BRL) supplemented with 10% FBS. 293T cells were seeded and
grown to 40–50% confluence in eight-chamber culture slides (BD
Falcon; 354108). Effectene was used for transfection according to
the manufacturer’s instructions (Qiagen, Inc). After 24 hours,
media were collected, and the cells were used for immunostaining.
The expression plasmid for human IFN-a2 is a gift from Dr. Blake
Roessler [86]. Human IFN-beta expression plasmid was pur-
chased from OriGene (SC127861). IRF7 dominant negative
mutant (IRF7-DN) and CD4 expression plasmids are described
previously [56,67,87]. Western blot analysis was essentially the
same as described previously [55,88,89]. shLuc was also described
previously [90]. shIRF7 was the mixture of shIRF71, -72, and -73
in a 1:1:1 ratio. The shIRF71(target sequence (59-
TGGCCCGCCCCCCGAGGCT-39), shIRF72 (59-
AATGGCCTTGGCTCCTGAG-39), and shIRF73 (59-
GCCCGCGGCAGGTGGCCGC-39) were all cloned into the
pHP vector, an shRNA expression plasmid [46]. The target
sequences were confirmed by sequencing analysis. LMP1 antibody
(CS1-4) was purchased from Dako. GAPDH antibody was
obtained from Santa Cruz Biotechnology Inc (sc-47724). Tubulin
(T6557) and FLAG antibody (F1804) were obtained from Sigma.
Reverse Transcriptase (RT)-Polymerase Chain Reaction
(RT-PCR)
RNA was extracted from cells using the TRIzol method, and
was synthesized into cDNA using Superscript II RT from
Invitrogen. The cDNA was then used in a PCR reaction with
primers for LMP1 and Actin. Primer sequences for LMP1 were
59– CCCAAGCTTTTAGTCATAGTAGCTTAGCTG – 39 and
59 – CGGGATCCGGAGGTGGCGGTGGACATGGACCAC-
Table 1. Detection of cellular IFN and viral LMP1 in lupus patients.
Patient # SELENA SLEDAI IFN LMP1 Co-expression in same cells Descriptor
1 8 + + + Arthritis (4), Pleurisy (2), Increased DNA Binding (2)
2 6 + + + Arthritis (4) Increased DNA Binding (2)
3 8 + + 2 Arthritis (4) Low Complement (2) Increased DNA
Binding (2)
4 8 + 2 2 Arthritis (4) Low Complement (2) Increased DNA
Binding (2)
5 6 + + + Arthritis (4) Rash (2)
6 10 + + + Arthritis (4) Rash (2) Low Complement (2)
Increased DNA Binding (2)
7 14 + + + Arthritis (4) Myositis (4) Rash (2) Low Complement
(2) Increased DNA Binding (2)
8 2 + + + Low Complement (2)
9 8 + + + Arthritis (4) Low Complement (2) Increased DNA
Binding (2)
10 6 + + 2 Arthritis (4) Low Complement (2)
11 6 + 2 2 Arthritis (4) Low Complement (2)
12 12 + + + Arthritis (4) Proteinuria (4) Rash (2) Increased DNA
Binding (2)
13 6 + + + Arthritis (4) Low Complement (2)
14 9 + 2 2 Arthritis (4) Low Complement (2) Increased DNA
Binding (2) Leukopenia (1)
15 9 + 2 2 Arthritis (4) Low Complement (2) Increased DNA
Binding (2) Leukopenia (1)
16 6 + + + Arthritis (4) Thrombocytopenia (1) Leukopenia (1)
17 5 + + 2 Arthritis (4) Leukopenia (1)
18 5 + + + Arthritis (4) Leukopenia (1)
19 8 + + 2 Proteinuria (4) Rash (2) Increased DNA Binding (2)
20 8 + + + Arthritis (4) Rash (2) Increased DNA Binding (2)
N1 N/A + 2 2 N/A
N2 N/A 2 2 2 N/A
N3 N/A 2 2 2 N/A
N4 N/A 2 2 2 N/A
N5 N/A + 2 2 N/A
N6 N/A 2 2 2 N/A
The SELENA-SLEDAI scores and the various descriptors at the time of blood collections are listed. The positive cells were identified by expression intensity similar to the
positive control (Figure 5E). The numbers of cells for either IFN-alpha or LMP1-postive are very few, and the percentages could not be used to represent the frequency. If
several positive cells were positively identified in a specimen, the score ‘‘+’’ was given. However if two or fewer positive cells were identified in approximate 56106
PBMC, it were scored as negative (2). The reason to use two positive cells as a cutoff was to avoid any artificial signals. N1–N6: normal, healthy individuals’ bloods.
doi:10.1371/journal.pone.0043317.t001
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GACACACTGATGAACACCACCAC – 39. The primers for
Actin were 59 – TTCTACAATGAGCTGCGTGT – 39 and 59 –
GCCAGACAGCACTGTGTTGG – 39. Primer sequences for
TLR3 were 59-GCATTTGTTTTCTCACTCTTT -39and 59-
TTAGCCACTGAAAAGAAAAAT-39 Primer sequences for
TLR7 were 59-AAACTCCTTGGGGCTAGATG -39and 59-
AGGGTGAGGTTCGTGGTGTT-39. Primer sequences for
TLR9 were 59-CGCCCTGCACCCGCTGTCTCT-39 and 59-
CGGGGTGCTGCCATGGAGAAG-39.
Transfection and Enrichment of Transfected Cells
Electroporation (300 V; 975 microfarads) was used for trans-
fection of the IB4 cells with total 5 mg of DNA including 1 mg of
CD4-expression plasmids. One or two days after transfection, the
cells were treated with or without imiquimod (5–10 mg/ml) for
24 hours. Enrichment for CD-4-positive cells was performed with
the use of anti-CD-4-antibody conjugated to magnetic beads
according to the manufacturer’s recommendation (Dynal, Inc.).
TLR Treatment and IFN-a Measurement
TLR agonists, poly(I:C) (tlrl-pic) for TLR3 stimulation (10 mg/
ml), imiquimod (tlrl-img) for TLR7 stimulation (5–10 mg/ml), and
ODN 2395(tlrl-2395) for TLR9 stimulation (2–5 mM) were
purchased from Invivogen. In addition, imiquimod (IMG-2207-
1) was also obtained from Imgenex. While different batches and
sources of imiquimod often gave similar results, the batch of FBS
may influence the outcomes of the treatments. For TLR7
potentiating experiments, imiquimod was used to treat cells for
12 hours and then cells were treated with other reagents. The
supernatants were used for IFN measurements. The concentration
of IFN-a was determined by a commercially available human
interferon alpha (Hu-IFN-alpha) ELISA kit (PBL Biomedical
Laboratories; catalog number 41100) according to the manufac-
turer’s recommendations. The kit is capable of detecting several
human IFN-alpha subtypes, but not IFN-beta. Samples were
measured in duplicates.
Ethics Statement
The research was approved by the Institutional Review Board
(IRB) of the University of Nebraska-Lincoln.
Patients’ and Healthy Individuals’ Bloods
After informed consent, whole blood samples from 20 lupus
patients were collected at the Arthritis Center of Nebraska and
immediately sent to The University of Nebraska-Lincoln. The
Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)
scale, as modified by the Safety of Estrogen in Lupus Erythema-
tosus National Assessment (SELENA) scores, were calculated
following standard procedures on each patient at the time of blood
draw [91,92,93]. Heparin was used as the anticoagulant. The fresh
whole bloods from healthy individuals were purchased from Zen-
Bio, Inc (SER-WB10ML). These bloods were processed immedi-
ately upon on arrival.
Isolation of Peripheral Blood Mononuclear Cells (PBMC)
Blood was diluted with 16 Phosphate Buffered Saline (PBS).
PBMCs were isolated from blood with the use of Ficoll-PaqueTM
PLUS following manufacturer’s recommendations (GE Health-
care). PBMC were collected and counted and some are directly for
the fixation process, others suspended in 10% DMSO and 90%
FBS and stored in a liquid nitrogen tank for future analysis.
Immunocytochemistry Analysis
Cells were aliquoted into 1.5 mL centrifuge tubes, and spun
down for 1 minute at 4,000 rpm in a microcentrifuge. Cells were
washed with 1XPBS for 5 minutes and then fixed with 1 mL 4%
Paraformaldehyde for 15 minutes. Cells were then rinsed twice in
PBS, permeabilized with 95% cold methanol at 220uC for
5 minutes, and allowed to dry on poly-lysine slides. Cells on slides
were washed twice with 16PBS in a gently shaken slide container,
and then blocked with PBST (1XPBS+ 0.5% Tween 20) including
3% BSA for 30 minutes. The slides were kept in the dark for the
remainder of the experiment. The cells were incubated in primary
antibodies with 1:100 dilutions for LMP1 [CS1-4 (DAKO) or S-12
(BD-Pharmingen)] and 1:50 dilution for human IFN-alpha
antibody (PBL Biomedical Laboratories; 31101-1) in PBST with
1% BSA for 1.5 hours, washed with PBST, then incubated for one
hour with secondary antibodies in 1:500 in PBST with 1% BSA.
The secondary antibodies were from Invitrogen (Alexa Fluor 647-
Alexa FluorH 647 goat anti-mouse IgG (H+L); A-21235 and Alexa
FluorH 488 donkey anti-rabbit IgG (H+L); A21206). Cells were
washed three times, stained with 49,6-diamidino-2-phenylindole
(DAPI) for 5 minutes, and washed and mounted with Gel Mount
Aqueous Mounting Medium and let air dry in the dark for at least
1 hour. Slides were kept at 4uC before examination with confocal
microscopy. All samples were screened using single excitation laser
line/single emission display at 405 nm/420 nm, 488 nm/522 nm,
or 633 nm/660 nm, for nuclear stain, IFN or LMP1 signals,
respectively. Optical images were collected under the same
conditions/confocal settings for negative/positive controls and
patients’ samples, using the sequential scanning and simultaneous
display mode of an Olympus FV500 confocal imaging system.
Supporting Information
Figure S1 A. TLR7 agonist increase LMP1 RNA. SavIII cells
were treated with TLR7 agonist (imiquimod; 25 mg/ml) for
24 hours. RNA was isolated and RT-PCR was employed to
examine LMP1 RNA expression. Proper primers were used for
detection of LMP1 and actin RNA respectively. PCR DNAs were
separated in 8% polyacrylamide gels. The plus or minus RT for
Figure 6. Potential exacerbating role of EBV in lupus patho-
genesis via IFNs. EBV infection increases the expression of TLR7. EBV-
infected cells may respond to TLR7 stimulators present in lupus
patients, and increase the expression levels of LMP1; LMP1 primes the
cells for IFN production; TLR3 and TLR9 stimulators induce IFN
production in those EBV-infected cells. High amounts of IFNs would
be responsible for more auto-antibody productions, cell/tissue dam-
ages, and eventually more self-nucleotide complexes containing various
TLR activators, including for TLR7; TLR7 activation again may promote
more LMP1 expression.
doi:10.1371/journal.pone.0043317.g006
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cDNA synthesis was used as a control. Input amount were shown.
Size of the DNA markers is as shown on the left in base pairs (bp).
The identity of target RNA is as shown. B. Expression of TLRs in
EBV-transformed cells. RNA was isolated from SavIII and IB4
cells, and RT-PCR was employed to examine various TLR
expression. PCR DNAs were separated in 8% polyacrylamide gels.
The plus or minus RT for cDNA synthesis was used as a control.
Size of the DNA markers is as shown on the left in base pairs (bp).
(TIF)
Figure S2 Cells with high LMP1 are increased upon
TLR7 activation. SavIII cells were treated with TLR7 agonist
(imiquimod; 10 mg/ml) for 12 hours, and the cells were then fixed
for immunestaining experiments. LMP1 and Alexa Fluor 647-
labeled secondary antibodies were used. DAPI was used to stain
the nuclei. Blue, nuclei; red, LMP1. Identical settings were used to
capture the images.
(TIF)
Figure S3 TLR7 activation failed to induce EBV lytic
replication in EBV-transformed cells. IB4 and Sav III were
treated with imiquimod (25 mg/ml) overnight. The positive control
was Akata cells treated with anti-human IgG. Cell lysates from
were used for Western blot analysis with LMP1 and Tubulin
antibodies. The membrane was stripped and probed with another
antibody. The images in the same box indicate that they are
derived from the same membranes. The identity of proteins is as
shown.
(TIF)
Figure S4 Specificity of the IFN-a antibody. 293T cells
were transfected with expression plasmid for IFN-a2, IFN-b, or
pcDNA3 (vector control) respectively. 24 hours after transfection,
cells were stained with IFN-a antibody. Alexa Fluor 488-labeled
secondary antibody was used to detect the expression. DAPI was
used to stain the nuclei. The colors were artificially mounted to
facilitate viewing. Blue, nuclei; green, IFN. The expression of IFN-
b was confirmed by a functional assay (data not shown).
(TIF)
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